A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial Saifudin.

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Responsiveness and minimal important difference of the urticaria control test Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria Ragip Ertas, MD, Kemal Ozyurt,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Dennis K. Ledford, MD, Sally Wenzel, MD

Shyam Joshi, MD, David A. Khan, MD

Is 9 more than 2 also in allergic airway inflammation?

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Children with allergic and nonallergic rhinitis have a similar risk of asthma Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.

Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria Sarbjit S. Saini, Theodore A. Omachi, Benjamin.

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Treatment of chronic autoimmune urticaria with omalizumab

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Sharon Seth, MD, David A. Khan, MD

John A. Eckman, MD, Patricia M

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

Jeffrey M. Harris, MD, PhD, Christopher R

Real-life treatment of cholinergic urticaria with omalizumab

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

High prevalence of severe asthma in a large random population study

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria Katja Koch, Karsten Weller, MD, Andreas Werner,

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Problem solving to improve adherence and asthma outcomes in urban adults with moderate or severe asthma: A randomized controlled trial Andrea J. Apter,

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria Sridharan Soundararajan, PhD, Yoko Kikuchi, DVM, Kusumam Joseph, PhD,

Lisa A. Beck, MD, Sarbjit Saini, MD

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

The Editors’ Choice Journal of Allergy and Clinical Immunology

Primary prevention of asthma and allergy

Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years Malgorzata Setkowicz, MD, PhD, Lucyna Mastalerz,

Brian F. Leas, MS, MA, Kristen E. D'Anci, PhD, Andrea J

Presentation transcript:

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria Sarbjit Saini, MD, Karin E. Rosen, MD, PhD, Hsin-Ju Hsieh, PhD, Dennis A. Wong, MD, Edward Conner, MD, Allen Kaplan, MD, Sheldon Spector, MD, Marcus Maurer, MD Journal of Allergy and Clinical Immunology Volume 128, Issue 3, Pages 567-573.e1 (September 2011) DOI: 10.1016/j.jaci.2011.06.010 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Study design. OMA, Omalizumab. Journal of Allergy and Clinical Immunology 2011 128, 567-573.e1DOI: (10.1016/j.jaci.2011.06.010) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Flow diagram based on Consolidated Standards of Reporting Trials (CONSORT) guidelines. OMA, Omalizumab. Journal of Allergy and Clinical Immunology 2011 128, 567-573.e1DOI: (10.1016/j.jaci.2011.06.010) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Mean ± SD for changes from baseline to week 4 in UAS7. P values are based on comparison with the placebo group by using the Van Elteren test. OMA, Omalizumab. Journal of Allergy and Clinical Immunology 2011 128, 567-573.e1DOI: (10.1016/j.jaci.2011.06.010) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Mean change from baseline in UAS7 by week during the treatment period. Journal of Allergy and Clinical Immunology 2011 128, 567-573.e1DOI: (10.1016/j.jaci.2011.06.010) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Mean ± SD for changes from baseline to week 4 in weekly itch and weekly hive scores. P values are based on comparison with the placebo group by using the Van Elteren test. Journal of Allergy and Clinical Immunology 2011 128, 567-573.e1DOI: (10.1016/j.jaci.2011.06.010) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions